C-Telopeptide (CTX) Blood Test: Normal Range, High & Low Results, and What It Means for Bone Health

QUICK ANSWER

CTX stands for C-Terminal Telopeptide — a fragment of bone collagen released into the blood when bone tissue is broken down. It is one of the most widely used bone resorption markers in clinical practice.

CTX is a bone breakdown marker. Higher CTX means faster bone loss; lower CTX means slower bone loss.

C-Telopeptide (CTX) measures the rate of bone resorption — the rate at which bone tissue is being broken down. When bone collagen degrades, CTX fragments are released into the bloodstream, making CTX a direct measure of how actively bone is being resorbed.

Should CTX be high or low? Lower is generally better. A lower CTX indicates slower bone breakdown, which is favorable for bone health. High CTX signals accelerated bone resorption — the faster bone breaks down, the higher the fracture risk.

Normal ranges by sex and menopausal status (LabCorp):

Note: These ranges are wide because CTX varies significantly with age, menopausal status, time of day, and fasting status. Always compare your result to the reference range on your specific lab report.

Quick number lookup — general orientation (postmenopausal women and men over 50):

These values are orientation guides only — interpret against your lab's sex- and age-specific reference range.

Key takeaway: CTX measures bone breakdown speed. Low or decreasing CTX is the goal for patients on osteoporosis treatment. A very low CTX on bisphosphonate therapy may warrant monitoring for over-suppression of bone turnover.

WHAT IS C-TELOPEPTIDE (CTX)?

C-Telopeptide (CTX) is a fragment of type I collagen — the primary structural protein in bone. During normal bone remodeling, osteoclasts (bone-dissolving cells) break down the collagen matrix, releasing CTX fragments into the bloodstream. The concentration of CTX in serum therefore reflects the rate at which bone tissue is being actively resorbed.

CTX as a bone resorption marker: CTX is one of the most widely used and best-validated bone turnover markers in clinical practice, recommended by the International Osteoporosis Foundation (IOF) as the preferred marker of bone resorption. It is measured alongside or compared to bone formation markers — particularly P1NP (procollagen type I N-terminal propeptide) — to provide a complete picture of bone turnover.

Full names and related terms you may see on your report:

• C-Telopeptide, Serum
• C-Telopeptide Beta-Cross-Linked, Serum
• Collagen Type I C-Telopeptide (CTX)
• Beta-CrossLaps
• S-CTX or Serum CTX
• CTX-1

All of these refer to the same test.

SHOULD C-TELOPEPTIDE BE HIGH OR LOW?

Lower CTX is better for bone health.

CTX measures the rate of bone breakdown. A lower value means bone is breaking down more slowly, which preserves bone density and reduces fracture risk. A higher value means bone is being resorbed faster — associated with bone loss, osteoporosis progression, and increased fracture risk.

What this means in practice:

On osteoporosis treatment: A 25–50% reduction in CTX within 3–6 months of starting bisphosphonate therapy (alendronate, risedronate, zoledronate) or denosumab is considered a positive treatment response. Very aggressive CTX suppression (near-zero values) over many years has been associated with atypical femoral fractures — a rare but recognized complication of long-term anti-resorptive therapy.

C-TELOPEPTIDE NORMAL RANGE: BY AGE AND MENOPAUSAL STATUS

Reference ranges for CTX are wider than most biomarkers because bone turnover naturally varies substantially across the lifespan.

Premenopausal women tend to have relatively lower CTX because estrogen suppresses osteoclast activity and restrains bone resorption. After menopause, the loss of estrogen accelerates bone resorption — CTX typically rises significantly in the first 5–10 years post-menopause.

C-telopeptide postmenopausal range: The upper limit of normal doubles or more after menopause (up to ~1,000 pg/mL on LabCorp), reflecting this physiological acceleration of bone turnover. A result that would be high in a premenopausal woman may be within the expected postmenopausal range.

Men show a more gradual increase in CTX with age as testosterone levels decline and bone turnover regulation diminishes. Men over 50 have a wider normal range than younger men.

Why fasting matters: CTX levels peak in the early morning (approximately 4–8 AM) and are lowest in the late afternoon. Food intake — particularly calcium — suppresses CTX acutely. For reproducible results, blood should be drawn in the morning after an overnight fast. Results from non-fasting samples may be up to 30–40% lower than fasting values.

WHAT DOES HIGH C-TELOPEPTIDE MEAN?

High CTX means bone resorption is accelerated — bone collagen is being broken down faster than expected for the patient's age and sex.

Common causes of high CTX:

• Osteoporosis or osteopenia — the most common cause; bone is being lost faster than it is being replaced
• Postmenopausal bone loss — estrogen deficiency markedly accelerates bone resorption
• Hyperparathyroidism — elevated PTH directly stimulates osteoclast activity and bone resorption
• Hyperthyroidism — thyroid hormone excess increases bone turnover
• Paget's disease of bone — markedly elevated CTX; often 3–10× above the normal range
• Bone metastases — cancer cells in bone tissue stimulate osteoclast activity; CTX tracks bone destruction in metastatic disease
• Vitamin D deficiency — secondary hyperparathyroidism from low vitamin D drives bone resorption
• Glucocorticoid/corticosteroid use — steroids increase bone resorption and decrease bone formation
• Immobilization — prolonged bed rest or inactivity reduces mechanical loading and increases bone resorption
• Multiple myeloma — osteolytic lesions from plasma cell infiltration

WHAT DOES LOW C-TELOPEPTIDE MEAN?

Low CTX most commonly reflects successful suppression of bone resorption — usually from anti-resorptive medication.

Common causes of low CTX:

• Bisphosphonate therapy (alendronate, risedronate, ibandronate, zoledronate) — the primary mechanism of these drugs is osteoclast inhibition; CTX falls substantially within weeks of starting treatment
• Denosumab (Prolia, Xgeva) — RANK-L inhibitor that powerfully suppresses bone resorption; produces among the lowest CTX values seen clinically
• Hormone replacement therapy (HRT) — estrogen replacement in postmenopausal women reduces CTX toward premenopausal levels
• Adynamic bone disease — a complication of chronic kidney disease (CKD) where bone turnover is severely suppressed; CTX is very low
• Malnutrition or severe caloric restriction — limits the substrate for bone turnover
• Hypothyroidism — low thyroid hormone slows bone turnover
• Hypoparathyroidism — low PTH reduces bone resorption signaling

Over-suppression concern: In patients on long-term bisphosphonate therapy (typically > 5–7 years), very low CTX (< 40 pg/mL or near-zero) may indicate that bone turnover has been suppressed below healthy levels. This has been associated with atypical femoral fractures. Many clinicians use CTX to guide decisions about bisphosphonate drug holidays.

CTX AND P1NP: INTERPRETING BONE TURNOVER TOGETHER

CTX and P1NP are the two recommended bone turnover markers by the International Osteoporosis Foundation (IOF) for clinical use:

The CTX/P1NP pattern:

• Both elevated: High bone turnover state — postmenopausal, hyperparathyroidism, Paget's
• CTX high, P1NP normal/low: Uncoupled resorption-dominant pattern — seen in bone metastases, myeloma
• CTX low, P1NP low: Over-suppression or adynamic bone — review bisphosphonate duration
• CTX decreasing, P1NP stable: Good response to anti-resorptive therapy

WHEN TO FOLLOW UP

Discuss your CTX result with a clinician if:

• CTX is significantly above the age/sex-appropriate normal range without an obvious cause
• You are on bisphosphonate therapy and CTX is not declining — may indicate poor absorption or adherence
• You are on long-term bisphosphonate therapy (> 5 years) and CTX is extremely low — discuss bisphosphonate holiday
• CTX is markedly elevated (> 3× upper limit of normal) — evaluate for Paget's disease, bone metastases, or hyperparathyroidism
• CTX is low but you are NOT on anti-resorptive therapy — consider hypothyroidism, malnutrition, or adynamic bone

BOTTOM LINE

Bottom line: CTX is a blood marker of bone resorption. Lower CTX is better — it means bone is breaking down more slowly. Normal ranges vary significantly by sex and menopausal status (premenopausal women: 40–465 pg/mL; postmenopausal: 104–1,008 pg/mL). High CTX indicates accelerated bone resorption from osteoporosis, hormonal changes, Paget's disease, or bone metastases. Low CTX on anti-resorptive therapy confirms treatment response. Always interpret CTX alongside P1NP, vitamin D, PTH, calcium, and DEXA results for a complete picture of bone health.

C-Telopeptide, Serum

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →

Beyond C-Telopeptide, Serum — 10,000+ markers explained

One C-Telopeptide, Serum result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.

Start with this report →

Frequently Asked Questions